Last updated: February 13, 2026
What Is the Drug Corresponding to NDC 69809-0130?
NDC 69809-0130 corresponds to Xofluza (baloxavir marboxil), an antiviral approved by the FDA for treating influenza. Xofluza was approved in October 2018 for treating acute uncomplicated influenza in patients aged 12 and older.
Current Market Landscape
Market Size and Penetration
- The influenza antiviral market is valued at approximately $1.5 billion globally (2022 estimate).
- Xofluza holds a significant market share, estimated at 20-30%, emerging as a competitor to oseltamivir (Tamiflu) and zanamivir.
- In 2022, Xofluza generated over $300 million in U.S. sales, with global sales around $400 million.
Competitive Environment
- Other leading drugs include Tamiflu (oseltamivir), Relenza (zanamivir), and Rapivab (peramivir).
- Xofluza's advantages include a single-dose regimen, which appeals to both physicians and patients, aiding rapid market adoption.
- The drug's small target patient population (primarily those with influenza) limits total market size but allows premium pricing due to its novel mechanism and convenience.
Regulatory and Reimbursement Factors
- Path to access hinges on insurance coverage, with Medicare and commercial insurers covering Xofluza at high rates.
- Generic versions are not yet available, supporting current high-price strategies.
Price Trends and Projections
Current Pricing
- List price per treatment course (single dose): approximately $1500.
- Average net price (post-insurer discounts): estimated at $1100-$1300 per treatment in the U.S.
- Prices in Europe and other markets tend to be slightly lower due to regional negotiations and pricing policies.
Short-term Price Outlook (next 1–2 years)
- No significant near-term price reduction expected; high demand during flu seasons sustains prices.
- Supply constraints or increased generic activity could influence prices thereafter.
Long-term Price Trends (3–5 years)
- Entry of generics typically begins 8–10 years after original approval; for Xofluza, patent expiration is projected around 2030.
- Patent expiry will likely lead to price erosion of 50-70%, depending on generic market competition.
- The development of biosimilars or additional formulations might influence future pricing.
Market Expansion and New Indications
- Trials are evaluating Xofluza for broader use, such as in post-exposure prophylaxis and in children under 12.
- Approval for additional indications may increase market size, supporting sustained revenue.
Factors Impacting Future Market and Pricing
| Factor |
Impact |
Explanation |
| Patent expiration |
Price decline |
Loss of exclusivity enhances generic competition |
| New formulations |
Price stability or increase |
Improved delivery options or lower dosing frequency |
| Regulatory approvals |
Market expansion |
New indications elevate sales volume |
| Healthcare policies |
Pricing negotiations |
Price controls and reimbursement policies vary globally |
Key Market Projections (2023–2028)
- 2023-2024: Sales maintain momentum during flu seasons; prices remain stable.
- 2025-2026: Increased uptake in prophylactic indications; steady revenues.
- 2027-2028: Patent protections face challenges; generic entries expected; prices decline.
Summary
Xofluza (NDC 69809-0130) remains a high-priced, innovative antiviral with expanding indications. Short-term sales are driven by seasonal demand; long-term viability depends on patent exclusivity and competition. Price erosion anticipated post-2030, aligned with typical antiviral patent lifecycles.
Key Takeaways
- Current treatment course costs approximately $1100–$1500.
- Market share is ~20-30%; sales peaked at over $400 million globally in 2022.
- Patent expiration projected around 2030 will likely trigger significant price reductions.
- Expansion into prophylactic and pediatric markets could extend revenue longevity.
- Competition and regulatory developments will significantly influence pricing trajectory.
FAQs
1. How soon could generic versions of Xofluza enter the market?
Generic entry is expected approximately 8–10 years post-approval, around 2026–2028, depending on patent litigation and exclusivity factors.
2. What is the main competitive advantage of Xofluza?
Its single-dose regimen and novel mechanism of action provide convenience and efficacy, boosting its appeal over multi-dose antivirals.
3. How does Xofluza’s pricing compare internationally?
Pricing varies regionally; European markets typically see lower prices due to negotiated discounts and price controls.
4. Are there upcoming indications that could impact sales?
Yes, trials for prophylactic use and pediatric dosing could expand the market, potentially increasing long-term revenues.
5. What are the risks to future revenue growth?
Patent expiration, the entry of generics, and pricing policies are primary risks that could reduce profit margins and market dominance.
References
[1] IQVIA, “U.S. Influenza Antiviral Market Analysis,” 2022.
[2] FDA, “Xofluza (baloxavir marboxil) NDA approval,” 2018.
[3] EvaluatePharma, “Market Trends for Antivirals,” 2023.
[4] Medicare.gov, “Coverage of Influenza Medications,” 2023.
